Joan Butterton, Merck Research Laboratories VP of global clinical development, infectious diseases (Merck)
October 25, 2021 09:21 AM EDT
R&D

Mer­ck­'s ex­per­i­men­tal HIV drug is­la­travir hits with a PhI­II com­bo win and FDA fil­ing plans

Paul Schloesser

Associate Editor

Back in March, Mer­ck and Gilead agreed to a part­ner­ship to chal­lenge Glax­o­SmithK­line on long-act­ing HIV meds — by com­bin­ing one drug from both Mer­ck …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times